Biopharmaceutical company
Biopharmaceutical company
Zymeworks completes its $929 million acquisition of Theravance Biopharma, adding a 35% US profit share in revefenacin (Yupelri) and a 20% share of any future ampreloxetine deal to its royalty-driven …
You must be logged in to post a comment.